Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01874431 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 823
- Enrollment target
NCT01874431: Completed Phase 2 study, sponsored by Bayer.
NCT01874431 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 823 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (519% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01874431, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 823 participants
- Enrollment target
Study Summary
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
Primary Outcome
Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.
Interventions
- DRUG Placebo
- DRUG Finerenone (BAY94-8862)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 823 participants |
| Start Date | 2013-06-12 |
| Est. Completion | 2014-08-07 |
| Phase | Phase 2 |
What the finished NCT01874431 record still lists
NCT01874431 is an interventional study that assigns participants to a tested intervention. The registered 823 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (519% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01874431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01874431 about?
NCT01874431 is a clinical study titled "Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy". To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
What is the current status of trial NCT01874431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 823 participants. The study started on 2013-06-12. Estimated completion is 2014-08-07.
What interventions are being tested in trial NCT01874431?
The interventions under investigation include: Placebo (DRUG), Finerenone (BAY94-8862) (DRUG).
Who is sponsoring clinical trial NCT01874431?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01874431's enrollment target sits among peer trials
823 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06944509 · 824 participants · NA
RADIQAL Study (Radiation Dose and Image Quality Trial)
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
- NCT06091254 · 822 participants · Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- NCT07357389 · 822 participants · NA
Virtual Reality for ICU Delirium Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI